Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 The Recently Leaked Secret to Marijuana News Discovered April 28, 2023 FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma August 12, 2021 WHO’s plans to create a ‘cervical cancer-free future’ April 19, 2021 Load more HOT NEWS COVID-19 Testing: What you need to know. Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma EMA Recommends Granting a Marketing Authorisation for Datopotamab Deruxtecan
